← Back to Search

Monoclonal Antibodies

OS2966 for Malignant Glioma

Phase 1
Waitlist Available
Research Sponsored by OncoSynergy, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests OS2966, a new antibody medicine, in adults with recurring or worsening high-grade brain tumors. The medicine is delivered directly to the tumor using a special technique to bypass the brain's protective barrier, aiming to stop cancer cells from growing and spreading.

Eligible Conditions
  • Malignant Glioma
  • Brain Tumor
  • Glioblastoma
  • Anaplastic Astrocytoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Optimal Biological Dose
Secondary study objectives
Spatial Distribution of OS2966 when delivered via CED
Tumor Response Rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Direct Infusion of OS2966Experimental Treatment2 Interventions
OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gadoteridol
2023
Completed Phase 3
~750

Find a Location

Who is running the clinical trial?

OncoSynergy, Inc.Lead Sponsor
Infuseon Therapeutics, Inc.Industry Sponsor
3 Previous Clinical Trials
12 Total Patients Enrolled
~1 spots leftby Nov 2025